Tom Daniel has more than 20 years of experience leading and building research and development organizations and leading investments in new companies at the forefront of innovative application of science to healthcare. Recently he served as a Venture Partner at ARCH Venture Partners for five years following a decade as President of Global Research and Early Development at Celgene Corporation. He previously served in senior leadership roles at AmbRx, Amgen and Immunex. Tom was formerly a director at Juno, Epizyme, Sana, Larimar and Vir.  He currently serves as board chair at LocanaBio, Gate Therapeutics and Trotana, and is director at Vividion, Gossamer Bio, Aspen and Mozart. He chairs the Board of Managers of Life Science Cares-San Diego, is a Trustee of Reed College, is a director at Scripps Research and Chair of the Board of Overseers.  He also serves as senior advisor to several private biotechnology companies. A nephrologist and former academic investigator, he was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. Dr. Daniel received his M.D. from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed his residency in Internal Medicine at Massachusetts General Hospital.